Mvasi and Kanjinti Launched
July 18, 2019 – Drug manufacturers Allergan and Amgen have announced the launch of biosimilars for two Genentech products. Mvasi™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), is indicated to treat metastatic colorectal cancer, non-small cell lung cancer, recurrent glioblastoma in adults, metastatic renal cell carcinoma, and persistent, recurrent, or metastatic cervical cancer. Kanjinti™ (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), is indicated to treat HER2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Mvasi first received U.S. FDA approval in 2017, while Kanjinti was approved in 2019. Each product’s recommended dosing is based on the patient’s body weight and the condition for which the patient is being treated. Kanjinti carries a black box warning for risk of cardiomyopathy, infusion reactions, embryo-fetal toxicity, and pulmonary toxicity.
Based on wholesale acquisition cost (WAC), both Mvasi and Kanjinti cost 15% less than their reference products. Mvasi is available at a WAC of $677.40 per 100mg vial and $2,709.60 per 400mg vial. Kanjinti has a WAC of $3,697.26 per 420mg vial. They are the first anticancer biosimilars to become available on the U.S. market.